Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone

European Psychiatry

Volumn 19, Issue 4, 2004, Pages 219-225

  Lasser, Robert A ^a   Bossie, Cynthia A ^a   Gharabawi, Georges M ^a   Turner, Martin ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Antipsychotic; Conventional; Depot; Long acting; Microspheres; Pharmacotherapy; Risperidone; Schizoaffective; Schizophrenia

Indexed keywords

LONG ACTING DRUG; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EXPERIENCE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; METHODOLOGY; MONOTHERAPY; PERFORMANCE; PHYSICIAN; PRIORITY JOURNAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STANDARD; SYMPTOMATOLOGY;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; RISPERIDONE; SCHIZOPHRENIA;

EID: 2942694109     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2003.11.007     Document Type: Article

References (21)

1. Weiden P., Zygmunt A. Medication noncompliance in schizophrenia. J Pract Psychiatry Behav Health. 3:1997;106-110
2. Dencker S.J. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. J Clin Psychiatry. 45:1984;22-27
3. Kane J.M., Aguglia E., Altamura A.C., et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol. 8:1998;55-66
4. Kane J.M. Pharmacologic treatment of schizophrenia. Biol Psychiatry. 46:1999;1396-1408
5. Babiker I.E. Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. J Clin Psychiatry. 48:1987;94-97
6. Davis J.M., Matalon L., Watanabe M.D., Blake L. Depot antipsychotic drugs: place in therapy. Drugs. 47:(5):1994;741-773
7. Masand P.S., Berry S.L. Switching antipsychotic therapies. Ann Pharmacother. 34:2000;200-207
8. Kane J.M. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol. 11:(Suppl 4):2001;S397-403
9. Csernansky J.G., Mahmoud R., Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Eng J Med. 346:2002;16-22
10. Dolder C.R., Lacro J.P., Dunn L.B., Jeste D.V. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry. 159:2002;103-108
11. Mahmoud R.A., Englehart M., Oster G., et al. Risperidone vs. conventional antipsychotics: a prospective randomized naturalistic effectiveness trial on outcomes in chronic schizophrenia. 36th Annual Meeting of the ACNP, Kamuela, Hawaii:1997
12. Kane J.M., Eerdekens M., Lindenmayer J.-P., et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 160:2003;1125-1132
13. Fleischhacker W.W., Eerdekens M., Karcher K., et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 64:2003;1250-1257
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed:1994;APA, Washington, DC
15. Clinical Global Impressions. Guy W. ECDEU Assessment Manual for Psychopharmacology. 1976;218-220 Department of Health, Education, and Welfare, Rockville, MD. Revised. DHEW Pub. No. (ADM) 76
16. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13:1987;261-276
17. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 58:1997;538-546
18. Chouinard G., Ross-Chouinard A., Annable L., Jones B.D. Extrapyramidal symptom rating scale. Can J Neurol Sci. 7:1980;233
19. Desai N.M., Huq A., Martin S.D., et al. Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. Adv Ther. 16:1999;78-88
20. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 151:1994;825-835
21. Davis J., Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull. 28:(1):2002;43-61